2026 Neurotrophic keratitis stage 3 indication strategy covering epidemiology, NGF biology, active trials, transactions, unmet need, competition and market…

2026 Aniridia-associated keratopathy indication strategy covering epidemiology, PAX6 biology, active trials, transactions, unmet need, competition and market…

2026 Keratoconus progressive indication strategy covering epidemiology, LOX biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Wolfram syndrome optic atrophy indication strategy covering epidemiology, WFS1 biology, active trials, transactions, unmet need, competition and market…

2026 Autosomal dominant optic atrophy indication strategy covering epidemiology, OPA1 biology, active trials, transactions, unmet need, competition and market…

2026 Choroidal osteoma indication strategy covering epidemiology, RANKL biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Gyrate atrophy of choroid and retina indication strategy covering epidemiology, OAT biology, active trials, transactions, unmet need, competition and market…

2026 Oguchi disease indication strategy covering epidemiology, SAG biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Norrie disease indication strategy covering epidemiology, NDP biology, active trials, transactions, unmet need, competition and market attractiveness.

2026 Polypoidal choroidal vasculopathy indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…

2026 Idiopathic juxtafoveal retinal telangiectasia indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition…

2026 Persistent fetal vasculature indication strategy covering epidemiology, VEGF biology, active trials, transactions, unmet need, competition and market…